- 學位論文
可溶性鳥苷酸環化酶活化劑cinaciguat藉由血管舒張及抗重塑效果而維持新生鼠的動脈導管暢通
The soluble guanylyl cyclase activator cinaciguat maintains postnatal patency of ductus arteriosus through vasodilatory and anti-remodeling effects in neonatal rats
摘要
在阻塞型先天性心臟疾病中，可透過注射前列腺素而維持動脈導管的暢通來拯救其性命，但也伴隨著許多藥物副作用。因此發現一個有效且安全的藥物，用以維持動脈導管暢通在兒童加護照顧中是很重要但卻缺乏的課題。動脈導管關閉包含兩個階段：血管收縮與重塑。我們假設可溶性鳥苷酸環化酶活化劑（soluble guanylyl cyclase (sGC) activator）cinaciguat透過sGC-PKG訊息使得動脈導管舒張及抗重塑來維持其暢通。在活體內實驗，我們逐一檢查cinaciguat（10 mg/kg腹內注射）作用在初生鼠出生第0及第2小時，在動脈導管型態及組織學上所表現出的效果。動脈導管的管徑通暢程度及重塑狀況將被檢視。在活體外實驗，初生鼠的動脈導管被分離出來，用以檢查cinaciguat對其血管張力的影響。在體外實驗，由初生鼠所分離培養的動脈導管平滑肌細胞被用以檢視抗重塑的機制。 結果顯示，初生鼠在出生2小時其動脈導管幾乎自行關閉，而在出生0小時使用cinaciguat可以預防動脈導管關閉，其動脈導管/主肺動脈外徑比值（DA/PA ratio）比控制組增加14.3%且空腔占比增加64.4%（p < 0.05)。在活體外實驗，cinaciguat（10-9~10-7 M）顯著地減弱氧氣所誘導的動脈導管收縮且有劑量依賴性效果。在體外實驗，cinaciguat抑制angiotensin II所誘發的動脈導管平滑肌增生及遷移。Cinaciguat抑制angiotensin II所誘發的ERK、JNK、p38及Akt訊息活化。總結，cinaciguat藉由血管擴張及抗重塑來防止出生後動脈導管的關閉。其中血管擴張及抗重塑的機制包含透過PKG訊號來減弱ERK、JNK、p38及Akt達到抗增生及抗遷移。因此sGC-PKG訊息路徑有希望成為臨床處置動脈導管上的治療標的。
並列摘要
Ductus arteriosus (DA) patency can be life-saving in some obstructive congenital heart lesions and is achieved by infusion of prostaglandin E1, which unfortunately has lots of side effects. Therefore, an effective and safe agent maintaining DA patency is important in pediatric intensive care but is lacking. DA closure consists of two phases: vasoconstriction and remodeling. We hypothesized that cinaciguat, a soluble guanylyl cyclase (sGC) activator, can maintain DA patency by vasodilatation and anti-remodeling through sGC-PKG signaling. In vivo, we serially examined effects of cinaciguat (10 mg/kg, ip) on DA morphology and histology in neonatal rats at 0 h and 2 h after birth. The degree of DA patency and remodeling were examined. Ex vivo, neonatal DA rings were used to examine effects of cinaciguat on vascular tone. In vitro, DA smooth muscle cells (DASMCs) cultured from neonatal rats were used to investigate mechanisms of anti-remodeling. We found that in control rats at 2h after birth, DA almost spontaneously closed. Cinaciguat at birth prevented DA closure with an increased DA/PA external diameter ratio by 14.3 % and an increased luminal patency by 64.4% than control at 2h. In addition, cinaciguat inhibited DA remodeling with a reduced intima/media diameter ratio of 21.9 % than control (p<0.05). Ex vivo, cinaciguat significantly attenuated oxygen-induced DA ring vasoconstriction in a dose-dependent manner (10-9~10-7 M). In vitro, cinaciguat inhibited antiotensin II (Ang II) -induced DASMC proliferation, migration. Finally, cinaciguat inhibited Ang II-induced ERK, JNK, p38 and Akt activation. In conclusion, cinaciguat prevents postnatal DA closure by both vasodilation and anti-remodeling. The mechanisms underlying vasodilatory and anti-remodeling effects consist of anti-proliferation and anti-migration, with attenuation of ERK, JNK, p38 and Akt signaling, through the PKG pathway. Therefore, sGC/PKG pathway can be a promising therapeutic target for clinical management of ductus arteriosus.
參考文獻
延伸閱讀
- 陳雅慧、李建興、許立松、羅慧珍（2013）。靜脈補充精胺酸對亞急性腹膜炎大鼠紅血球及腓腸肌的氧化及硝化壓力之影響。臺灣營養學會雜誌，38(2)，40-49。https://doi.org/10.6691/NSJ.201306_38(2).0002
- 彭婕妤（2008）。Baicalein, KS-5與YD-3對血管平滑肌及內皮細胞之生長調控作用及在血管再阻塞與血管新生之藥效評估〔博士論文，國立臺灣大學〕。華藝線上圖書館。https://doi.org/10.6342/NTU.2008.02441
- 林欣榮、周TL、宋文盛、蔣永孝（1996）。等量血液稀釋使老鼠部份前腦缺血時紅血球及血漿於腦部微血管通過延長正常化。腦中風會訊，3(2)，7-7。https://doi.org/10.6318/STROKE.199606_3(2).0007
- Hsieh, C. C., Hsieh, S. C., Chiu, J. H., & Wu, Y. L. (2014). Protective Effects of N-acetylcysteine and a Prostaglandin E1 Analog, Alprostadil, Against Hepatic Ischemia: Reperfusion Injury in Rats. Journal of Traditional and Complementary Medicine, 4(1), 64-71. https://doi.org/10.4103/2225-4110.124351
- Tisato, V., Zauli, G., Rimondi, E., Gianesini, S., Brunelli, L., EricaMenegatti, Zamboni, P., & Secchiero, P. (2013). Inhibitory Effect of Natural Anti-Inflammatory Compounds on Cytokines Released by Chronic Venous Disease Patient-Derived Endothelial Cells. Mediators of Inflammation, 2013(), 335-347-131. https://doi.org/10.1155/2013/423407